Amphista Therapeutics Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an F-Box only protein 22 (FBXO22)-binding moiety coupled to a transcriptional enhancer factor TEF (TEAD)-targeting moiety through a linker reported to be useful for the treatment of cancer.
Convalife Pharmaceuticals Co. Ltd. has presented data for their bispecific antibody CVL-006, which targets both PD-1 and VEGF-A. CVL-006 blocks both the PD-1-driven immune pathway plus VEGF-A-driven angiogenesis, thus conferring a dual mechanism for superior antitumoral activity.
Beijing Fuyuan Medicine Co. Ltd. has described compounds acting as monocarboxylate transporter 4 (MCT4) inhibitors reported to be useful for the treatment of cancer, asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis.
Littdd Medicines Ltd. has described mTOR complex 1 (mTORC1) and/or mTOR complex 2 (mTORC2) inhibitors reported to be useful for the treatment of cancer, idiopathic pulmonary fibrosis, transplant rejection, autoimmune and metabolic diseases, Huntington’s disease, Parkinson’s disease and Alzheimer’s disease, among others.
Bryet US Inc. has received Australian Human Research Ethics Committee (HREC) approval for its first-in-human study of ML-016 for patients with advanced cancer with lung and/or liver involvement. Enrollment in the phase I/II trial will begin early next year.
Zai Lab (Shanghai) Co. Ltd. and Zai Lab (US) LLC have divulged spirocyclic compounds acting as transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.
Boehringer Ingelheim Pharma GmbH & Co KG has advanced a novel T-cell engager resulting from a collaboration with Numab Therapeutics AG into preclinical development for the treatment of lung and gastrointestinal cancers.
A recently published study in the Journal for Immunotherapy of Cancer presents a novel bispecific antibody-cytokine fusion protein that effectively enhances antitumor immunity.
Non-small-cell lung cancer (NSCLC) accounts for up to 85% of all cases of lung cancer, which is the most frequent cause of cancer-related deaths worldwide. The need for effective treatments against NSCLC is urgent, and one promising target is pyruvate kinase M2, which plays metabolic and nonmetabolic roles in the cell. This enzyme has been implicated in various cancers beyond NSCLC, including pancreatic, gastric and breast cancers.
